Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 173

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 173
---
-  
     -  
     -  
     1,555,000 
  
    Issuance of Series A shares sold to investors, net 
     7,854  
     6,755,698  
     -  
     -  
     (856,663) 
     -  
     -  
     5,899,035 
  
    Issuance of Series A Preferred Warrants 
     -  
     -  
     -  
     -  
     2,000,000  
     (2,000,000) 
     -  
     - 
  
    Issuance of common stock to Keystone Capital LLC for equity line of credit 
     -  
     -  
     59  
     -  
     633,345  
     -  
     -  
     633,345 
  
    Opening Equity at February 14, 2024 (Successor) 
     10,089  
    $8,937,852  
     7,266  
    $1  
    $53,899,885  
    $(2,000,000) 
    $(63,185,641) 
    $(2,347,903)

12

NOTE 4 – NET LOSS PER SHARE OF COMMON
STOCK

The accounting standards
require the presentation of both basic and diluted earnings per share on the face of the statements of operations. The Company’s
basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of shares
of common stock outstanding for the period. If there are dilutive securities, diluted income per share is computed by including common
stock equivalents which includes shares issuable upon the exercise of stock options into shares of common stock, exercise of preferred
warrants into shares of preferred stock, and conversion of preferred stock into shares of common stock, net of any shares assumed to have
been purchased with the proceeds, using the treasury stock method. In periods for which the Company reports a net loss, the common stock
equivalents are not included, as they would be anti-dilutive.

The following table summarizes
the number of shares of Common Stock issuable upon conversion or exercise, as applicable, of convertible securities, stock options, and
warrants that were not included in